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2012-2013 Influenza Season 
Week 18 ending May 4, 2013 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 18 (April 28-May 4, 2013), influenza activity remained low in the United 
States. 
o Viral Surveillance: Of 3,048 specimens tested and reported by collaborating laboratories, 
125 (4.1%) were positive for influenza. 
o Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and 
influenza (P&I) was below the epidemic threshold. 
o Influenza-Associated Pediatric Deaths: One pediatric death was reported. 
o Influenza-Associated Hospitalizations: A cumulative rate for the season of 44.2 
laboratory-confirmed influenza-associated hospitalizations per 100,000 population was 
reported. Of reported hospitalizations, 50% were among adults 65 years and older. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 0.9%. This is below the national baseline of 2.2%. All 10 regions reported ILI below 
region-specific baseline levels. 49 states and New York City experienced minimal activity, 
and the District of Columbia and 1 state had insufficient data. 
o Geographic Spread of Influenza: 5 states reported regional influenza activity; 3 states 
reported local influenza activity; Guam, Puerto Rico, and 37 states reported sporadic 
influenza activity; 5 states reported no influenza activity, and the District of Columbia and the 
U.S. Virgin Islands did not report. 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/overview.htm. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since September 30, 2012 (Week 40) 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of 
jurisdictions 
reporting 
regional or 
widespread 
activity§  
2009 
H1N1 A (H3) 
A 
(Subtyping 
not perfor-
med) 
B  Pediatric Deaths 
Nation Normal 4.1% 5 of 54 1,430 33,214 16,700 20,843 138 
Region 1 Normal 9.6% 3 of 6 69 2,379 616 513 8 
Region 2 Normal 8.4% 1 of 4 202 2,521 2,127 1,591 21 
Region 3 Normal 6.1% 0 of 6 251 6,878 487 2,581 5 
Region 4 Normal 7.0% 0 of 8 141 2,580 6,483 4,061 22 
Region 5 Normal 15.4% 0 of 6 141 4,900 491 1,570 26 
Region 6 Normal 1.6% 0 of 5 84 2,125 3,218 3,961 27 
Region 7 Normal 2.4% 0 of 4 41 2,011 200 1,025 4 
Region 8 Normal 2.8% 0 of 6 213 2,949 1,955 3,033 11 
Region 9 Normal 8.0% 1 of 5 223 4,088 890 1,864 13 
Region 10 Normal 6.1% 0 of 4 65 2,783 233 644 1 
* http://www.hhs.gov/about/regionmap.html 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands. 
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U.S. Virologic Surveillance: U.S. World Health Organization (WHO) and National Respiratory and Enteric 
Virus Surveillance System (NREVSS) collaborating laboratories located in all 50 states and Puerto Rico report 
to CDC the number of respiratory specimens tested for influenza and the number positive by influenza virus 
type and influenza A virus subtype. 
 
 Week 18 
No. of specimens tested 3,048 
No. of positive specimens (%) 125 (4.1%) 
Positive specimens by type/subtype  
Influenza A 41 (32.8%) 
          2009 H1N1 4 (9.8%)  
          Subtyping not performed 29 (70.7%)
          H3 8 (19.5%)  
Influenza B 84 (67.2%) 
 
Influenza-Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2012-13 Season 
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The image below shows the proportion of influenza-positive respiratory samples by type and 
subtype for the most recent three weeks in each region. Regions with ILI above region-specific 
baseline levels are highlighted. Region-specific data can be found at 
http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
2012-13 Influenza Season – Week 18, ending May 4, 2013           
 
3
 
 
 
 
Antigenic Characterization: CDC has antigenically characterized 2,354 influenza viruses [234 
2009 H1N1 viruses, 1,305 influenza A (H3N2) viruses, and 815 influenza B viruses] collected by 
U.S. laboratories since October 1, 2012. 
 
2009 H1N1 [234] 
• 231 (98.7%) of the 234 2009 H1N1 viruses tested were characterized as 
A/California/7/2009-like, the influenza A (H1N1) component of the 2012-2013 influenza 
vaccine for the Northern Hemisphere. 
• 3 (1.3%) of the 234 2009 H1N1 viruses tested showed reduced titers with antiserum 
produced against A/California/7/2009. 
 
Influenza A (H3N2) [1,305]: 
• 1,300 (99.6%) of the 1,305 H3N2 influenza viruses tested have been characterized as 
A/Victoria/361/2011-like, the influenza A (H3N2) component of the 2012-2013 Northern 
Hemisphere influenza vaccine. 
• 5 (0.4%) of the 1,305 H3N2 viruses tested showed reduced titers with antiserum 
produced against A/Victoria/361/2011. 
 
Influenza B (B/Yamagata/16/88 and B/Victoria/02/87 lineages) [815]: 
 
• Yamagata Lineage [546]: 546 (67.0%) of the 815 influenza B viruses tested so far this 
season have been characterized as B/Wisconsin/1/2010-like, the influenza B component 
of the 2012-2013 Northern Hemisphere influenza vaccine. 
• Victoria Lineage [269]: 269 (33.0%) of 815 influenza B viruses tested have been from 
the B/Victoria lineage of viruses. 
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Composition of the 2013-2014 Influenza Vaccine:  The World Health Organization (WHO) has 
recommended vaccine viruses for the 2013-2014 Northern Hemisphere vaccines, and the Food and 
Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) 
has made recommendations for the composition of the 2013-2014 influenza vaccines to be used in 
the United States.  Both agencies recommend that trivalent vaccines contain an 
A/California/7/2009-like (2009 H1N1) virus, an A(H3N2) virus antigenically like the cell-propagated, 
or cell-grown, virus A/Victoria/361/2011 (A/Texas/50/2012), and a B/Massachusetts/2/2012-like 
(B/Yamagata lineage) virus.  It is recommended that quadrivalent vaccines containing an additional 
influenza B virus contain a B/Brisbane/60/2008-like (B/Victoria lineage) virus in addition to the 
viruses recommended for the trivalent vaccines. These recommendations were based on global 
influenza virus surveillance data related to epidemiology and antigenic characteristics, serological 
responses to 2012-2013 seasonal vaccines, and the availability of candidate strains and reagents. 
 
 
Antiviral Resistance: Testing of 2009 H1N1, influenza A (H3N2), and influenza B virus isolates for 
resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a 
functional assay. Additional 2009 influenza A (H1N1) clinical samples are tested for a single 
mutation in the neuraminidase of the virus known to confer oseltamivir resistance (H275Y). The 
data summarized below combine the results of both testing methods. These samples are routinely 
obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be 
infected with antiviral-resistant virus. 
 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 
influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B 
viruses). As a result, data from adamantane resistance testing are not presented below. 
 
Neuraminidase Inhibitor Resistance Testing Results 
on Samples Collected Since October 1, 2012 
 
Oseltamivir Zanamivir 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza A 
(H3N2) 2,086* 2 (0.1) 2,086* 0 (0.0) 
Influenza B 898 0 (0.0) 898 0 (0.0) 
2009 H1N1 525* 2 (0.4) 247 0 (0.0) 
*Includes specimens tested in national surveillance and additional specimens tested at public health 
laboratories in 11 states (AZ, DE, HI, ME, MD, MI, MN, NY, PA, WA, and WI) who share testing results 
with CDC. 
 
The majority of currently circulating influenza viruses are susceptible to the neuraminidase inhibitor 
antiviral medications, oseltamivir and zanamivir; however, rare sporadic cases of oseltamivir-
resistant 2009 H1N1 and A (H3N2) viruses have been detected worldwide. Antiviral treatment with 
oseltamivir or zanamivir as early as possible is recommended for patients with confirmed or 
suspected influenza who have severe, complicated, or progressive illness; who require 
hospitalization; or who are at greater risk for serious influenza-related complications. Additional 
information on recommendations for treatment and chemoprophylaxis of influenza virus infection 
with antiviral agents is available at http://www.cdc.gov/flu/antivirals/index.htm. 
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Novel Influenza A Virus: No new human infections with novel influenza A viruses in the United 
States were reported to CDC during week 18. 
 
On April 1, 2013, the World Health Organization (WHO) first reported 3 human infections with a new 
influenza A (H7N9) virus in China. Since then, additional cases have been reported. Most reported 
cases have severe respiratory illness and, in some cases, have died. At this time, no cases of 
H7N9 outside of China have been reported. The new H7N9 virus has not been detected in people 
or birds in the United States. 
 
Pneumonia and Influenza (P&I) Mortality Surveillance: During week 18, 7.0% of all deaths 
reported through the 122 Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 7.2% for week 18. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending May 4, 2013 
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Influenza-Associated Pediatric Mortality: One influenza-associated pediatric death was reported 
to CDC during week 18.  This death was associated with an influenza A virus for which the subtype 
was not determined and occurred during week 6 (week ending February 9, 2013). 
 
A total of 138 influenza-associated pediatric deaths have been reported during the 2012-2013 
season from Chicago [2], New York City [4] and 37 states (AL [1], AR [4], AZ [4], CA [4], CO [5], FL 
[8], GA [2], HI [2], IA [1], IL [2], IN [4], KS [2], KY [2], LA [2], MA [4], MD [3], ME [1], MI [6], MN [4], 
MS [1], NE [1], NH [3], NJ [7], NM [3], NV [3], NY [10], OH [4], OK [1], PA [1], SC [5], SD [3], TN [3], 
TX [17], UT [3], VA [1], WA [1], and WI [4]). 
 
Additional data can be found at http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2009-10 season to present 
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Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network 
(FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related 
hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) 
and adults (since the 2005-2006 influenza season).   
   
The FluSurv-NET covers more than 80 counties in the 10 Emerging Infections Program (EIP) states 
(CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and additional Influenza Hospitalization Surveillance 
Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance 
during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 
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season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT during the 
2011-2012 season; and IA, MI, OH, RI, and UT during the 2012-2013 season.  
 
Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and 
describe characteristics of persons hospitalized with severe influenza illness. The rates provided 
are likely to be an underestimate as influenza-related hospitalizations can be missed, either 
because testing is not performed, or because cases may be attributed to other causes of 
pneumonia or other common influenza-related complications.  
 
Between October 1, 2012 and April 30, 2013, 12,330 laboratory-confirmed influenza-associated 
hospitalizations were reported. This is a rate of 44.2 per 100,000 population. The most affected 
group is those ≥65 years, accounting for about 50% of reported cases. Among all hospitalizations, 
9,760 (79.2%) were associated with influenza A and 2,490 (20.2%) with influenza B. There was no 
virus type information for 46 (0.4%) hospitalizations. Among hospitalizations with influenza A 
subtype information, 3,697 (96.1%) were attributed to H3 and 143 (3.7%) were attributed to 2009 
H1N1. The most commonly reported underlying medical conditions among hospitalized adults were 
cardiovascular disease, metabolic disorders, obesity, and chronic lung disease (excluding asthma). 
The most commonly reported underlying medical conditions in hospitalized children were asthma, 
neurologic disorders, obesity, and immune suppression. Approximately 46% of hospitalized children 
had no identified underlying medical conditions.  Among 657 hospitalized women of childbearing 
age (15-44 years), 199 were pregnant, including 7 pregnancies among the 34 pediatric cases in this 
category.    
 
Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html 
and http://gis.cdc.gov/grasp/fluview/FluHospChars.html 
 
The current season’s influenza-associated hospitalization data includes patients admitted from 
October 1, 2012 through April 30, 2013; however, these data will continue to be updated as 
additional information is received. 
Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza 
related hospitalizations in children and adults in 15 US states. Incidence rates are calculated using the National Center for
Health Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area.
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Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular diseases include conditions 
such as coronary heart disease, cardiac valve disorders, congestive heart failure, and pulmonary hypertension (does not 
include isolated hypertension);  Chronic lung diseases include conditions such as bronchiolitis obliterans, chronic 
aspiration pneumonia, and interstitial lung disease;  Immune suppression includes conditions such as immunoglobulin 
deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications;  Metabolic disorders 
include conditions such as diabetes mellitus, thyroid dysfunction, adrenal insufficiency, and liver disease;  Neurologic 
diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction;  Neuromuscular 
diseases include conditions such as multiple sclerosis and muscular dystrophy;  Obesity was assigned if indicated in 
patient’s medical chart or if body mass index (BMI) >30 kg/m2;  Pregnancy percentage calculated using number of female 
cases aged between 15 and 44 years of age as the denominator;  Renal diseases include conditions such as acute or 
chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance;  No known condition 
indicates that the case did not have any known underlying medical condition indicated in medical chart at the time of 
hospitalization. 
Only includes cases for which data collection has been completed through the medical chart review stage. 
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Outpatient Illness Surveillance: Nationwide during week 18, 0.9% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.2%. 
 
(ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2012-13 and Selected Previous Seasons 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.5% to 1.5% during 
week 18. All 10 regions reported a proportion of outpatient visits for ILI below their region-specific 
baseline levels. 
 
Additional data can be found at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html 
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Region 6 - AR, LA, NM, OK, TX
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Region 2 - NJ, NY, USVI
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Region 3 - DE, DC, MD, PA, VA, WV
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
0
2
4
6
20
10
40
20
10
50
20
11
10
20
11
20
20
11
30
20
11
40
20
11
50
20
12
10
20
12
20
20
12
30
20
12
40
20
12
50
20
13
10
Week
%
 o
f V
is
its
 fo
r I
LI
  
Region 9 - AZ, CA, HI, NV
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ILINet Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during spring and fall weeks with 
little or no influenza virus circulation. Activity levels range from minimal, which would correspond to 
ILI activity from outpatient clinics being below the average, to high, which would correspond to ILI 
activity from outpatient clinics being much higher than average. 
 
During week 18, the following ILI activity levels were experienced: 
 Forty-nine states and New York City experienced minimal ILI activity (Alabama, Alaska, 
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, 
Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, 
New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, 
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, 
Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming). 
 Data were insufficient to calculate an ILI activity level for the District of Columbia and 1 state 
(South Dakota).  
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city 
could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports 
from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
 
During week 18, the following influenza activity was reported: 
 Five states reported regional influenza activity (Connecticut, Hawaii, Maine, Massachusetts, 
and New York). 
 Three states reported local influenza activity (Alaska, Ohio, and Pennsylvania). 
 Guam, Puerto Rico, and 37 states reported sporadic influenza activity (Alabama, Arizona, 
Arkansas, California, Colorado, Delaware, Florida, Illinois, Indiana, Iowa, Kentucky, 
Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New 
Hampshire, New Jersey, New Mexico, North Carolina, North Dakota, Oklahoma, Oregon, 
Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Vermont, Virginia, 
Washington, West Virginia, Wisconsin, and Wyoming). 
 Five states (Georgia, Idaho, Kansas, Mississippi, and Utah) reported no influenza activity. 
 The U.S. Virgin Islands and the District of Columbia did not report. 
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Additional National and International Influenza Surveillance Information 
 
FluView Interactive: This season, FluView includes enhanced web-based interactive applications 
that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These 
FluView Interactive applications allow people to create customized, visual interpretations of 
influenza data, as well as comparisons across flu seasons, regions, age groups and a variety of 
other demographics. To access these tools visit www.cdc.gov/flu/weekly/fluviewinteractive.htm.  
 
U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local 
influenza information. 
 
Alabama Alaska Arizona Arkansas California 
Colorado Connecticut Delaware District of Columbia Florida 
Georgia Hawaii Idaho Illinois Indiana 
Iowa Kansas Kentucky Louisiana Maine 
Maryland Massachusetts Michigan Minnesota Mississippi 
Missouri Montana Nebraska Nevada New Hampshire 
New Jersey New Mexico New York North Carolina North Dakota 
Ohio Oklahoma Oregon Pennsylvania Rhode Island 
South Carolina South Dakota Tennessee Texas Utah 
Vermont Virginia Washington West Virginia Wisconsin 
Wyoming New York City Virgin Islands 
 
Google Flu Trends: Google Flu Trends uses aggregated Google search data in a model created in 
collaboration with CDC to estimate influenza activity in the United States. For more information and 
activity estimates from the U.S. and worldwide, see http://www.google.org/flutrends/. 
 
World Health Organization: Additional influenza surveillance information from participating WHO 
member nations is available through FluNet and the Global Epidemiology Reports.  
 
WHO Collaborating Centers for Influenza located in Australia, China, Japan, and the United 
Kingdom.  
 
Europe: WHO/Europe at http://www.euroflu.org/index.php and the European Centre for Disease 
Prevention and Control at 
http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_survei
llance_overview.aspx. 
 
Public Health Agency of Canada: The most up-to-date influenza information from Canada is 
available at http://www.phac-aspc.gc.ca/fluwatch/. 
 
Health Protection Agency (United Kingdom): The most up-to-date influenza information from the 
United Kingdom is available at 
http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/ 
 
 
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not 
constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and 
none should be inferred. CDC is not responsible for the content of the individual organization web pages found 
at these links.  
 
